CD30: An important new target in hematologic malignancies

Yehuda E. Deutsch, Tamar Tadmor, Eckhard R. Podack, Joseph D. Rosenblatt

Research output: Contribution to journalReview articlepeer-review

58 Scopus citations


CD30 is abundantly and selectively expressed on the surface of Hodgkin ReedSternberg cells, anaplastic large cell lymphomas (ALCLs), and other lymphoid malignancies as well as on several non-lymphoid malignancies including selected germ cell tumors. Expression of CD30 on normal cells is highly restricted, thereby allowing differential targeting of malignant cells. CD30, a member of the tumor necrosis factor (TNF)-receptor family has pleiotropic biologic functions, and antibodies targeting CD30 and other TNF family receptors can exhibit both agonistic and antagonistic signaling functions. Recently, antibodydrug conjugates targeting CD30, such as brentuximab vedotin, have shown striking activity in phase I and II trials, with manageable toxicity. This has defined an important emerging role for targeting of CD30 in the setting of Hodgkin lymphoma, ALCL, and possibly other CD30+ malignancies.

Original languageEnglish (US)
Pages (from-to)1641-1654
Number of pages14
JournalLeukemia and Lymphoma
Issue number9
StatePublished - Sep 2011


  • antibody-based immunotherapy
  • brentuximab vedotin
  • CD30
  • Lymphoma and Hodgkin disease

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'CD30: An important new target in hematologic malignancies'. Together they form a unique fingerprint.

Cite this